Esomeprazole magnesium dihydrate - YooYoung Pharmaceutical
Alternative Names: YYD601Latest Information Update: 31 Oct 2021
At a glance
- Originator Yooyoung Pharmaceutical
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antibacterials; Antiulcers; Gastric antisecretories; Small molecules
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Erosive oesophagitis; Gastro-oesophageal reflux
- No development reported Peptic ulcer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux(In volunteers) in South Korea (PO)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Peptic-ulcer in South Korea
- 17 Jun 2019 Yooyoung Pharmaceutical plans a phase I trial for Gastro-oesophageal reflux disease (In volunteers) (NCT03985319)